alexa Analysis Of Adverse Effect Caused By AAV-2 Encoded Modified Volvox Channelrhdopsin-1 Gene Therapy
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

10th International Conference on Clinical & Experimental Ophthalmology
November 21-23, 2016 Dubai, UAE

Eriko Sugano
Iwate University, Japan
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.C1.048
Abstract
We designed a modified channelrhodopsin-1 (mVChR1) protein chimera, which has a broader, red-shifted action spectrum than that of Chlamydomonas channelrhodopsin-2. We previously reported that its transduction into retinal ganglion cells could restore visual function in genetically blind rats with photostimuli ranging from 486 to 640 nm. However, it has the possibility that mVChR1-mediated gene therapy causes some adverse effects such as immune response because of the use of the non-human gene. To investigate the safety and influence of mVChR1 transgene expression, adeno-associated virus type-2 encoding mVChR1 was administered by intra-vitreous injection into genetically blind rats. Reverse-transcription PCR was used to monitor transgene dissemination to non-targeted organs and the results demonstrated that their expression was restricted specifically within the eye tissues. Moreover, no excess immunoreactivity was present in standard clinical hematological parameters of plasma and serum. Serum antibodies targeting the recombinant adeno associated virus (rAAV) capsid increased after the injection; however, no increase in mVChR1 antibody was detected during for 10 months after the injection. In addition, retinal histological examination showed no signs of inflammation in rAAV-injected rats. In conclusion, our results demonstrate that mVChR1 can be exogenously expressed without harmful immunological reactions in vivo. These findings will help the optogenetic approach for restoration of vision in latestage retinitis pigmentosa.
Biography

Eriko Sugano has worked as a Researcher in Tohoku University School of Medicine in Japan and received PhD from Tohoku University in Life science. She has worked as an Instructor in Biomedical Engineering Research Organization and International Advanced Interdisciplinary Research, Tohoku University. She is the Associate Professor of Chemistry and Biological Sciences, Iwate University. She has published more than 30 papers in reputed journals.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords